Fatty Liver Disease in the U.S.

**Prevalence:**
By 2030, 100M Americans with Non-Alcoholic Fatty Liver Disease.

**Growth Drivers:**
Diabetes, obesity & sedentary lifestyle.

**Unmet Need:**
Existing diagnostic tools are expensive, inefficient, inaccurate, inaccessible.
MRI Capabilities
In Your Hand

Velacur™ the world’s first handheld 3D liver health assessment tool with diagnostic accuracy comparable to MRI.

Accurate
Accessible
Affordable
Fast
Easy to Use
Velacur™ Is Easy To Use

01 Activation

02 Ultrasound Scan

03 Readout

*Platform technology, patent protected
Immediate Results:
Elasticity and Attenuation

- Elasticity: 4.7 kPa
- Wave Speed: 1.3 m/s
- Reliability: 91%
- Attenuation: 275 dB/m
- Reliability: 82%

Overall Results (N=5):

- Median Elasticity: 4.7 kPa
- Median Wave Speed: 1.3 m/s
- Variability Elasticity: 15.9%
- Variability Wave Speed: 4.8%
Velacur™
Traction

Customer Pilots:
• 7 centres
• Representing 230 sites

NASH Drugs/Pharma:
• Multiple drug trials
• $15B market opportunity

Future:
• Nationwide GI/Hep
• Other specialties & primary care
• International markets
Sonic Incytes
An Accomplished Team

Leadership Team

George Aliphtiras, CEO
Founder and Former CEO
BioMers

Dr. Tim Salcudean
Co-founder and CTO
University of British Columbia Professor, Laszlo Chair in Ultrasound and Robotics

Dr. Robert Rohling
Co-founder and CSO
University of British Columbia Professor, ICICS Director in Ultrasound and AI

Joseph Lee, CFO
Former CFO, TerraMera

Brian Stachniak
Director of Product
Former Manager, McKesson Imaging

Jeffrey Haar
Director of Sales
Former National Sales Manager, Diversatek Health (GI Distributor), Echosens (FibroScan)

Board of Directors

Dr. Kenneth Moritsugu
Former US Deputy Surgeon General
Rear Admiral, US Public Health Service

Dr. Chris Nguan
Urologist
Head Kidney Transplant
Vancouver Coastal Health

Daniel Cordingley
Founder and Former CEO
Teradici

Natalie Dakers
Founder and Former CEO
Accel-Rx and CDRD
If you require further information, please contact us at:
George Aliphtiras, CEO
(+1) 604 727 4145
george@sonicincytes.com

Thank you for your time!